BTMD

Company Overview — What Does biote Corp. Do?

Haymaker Acquisition Corp. III does not have any significant operations. It intends to acquire and operate a business in the consumer and consumer-related products. The company was incorporated in 2020 and is based in New York, New York. biote Corp. (BTMD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Terry S. Weber. With a market capitalization of $44M, BTMD is one of the notable companies in the Healthcare sector.

biote Corp. (BTMD) Stock Rating — Reduce (April 2026)

As of April 2026, biote Corp. receives a Reduce rating with a composite score of 42.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BTMD ranks #3,243 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, biote Corp. ranks #490 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BTMD Stock Price and 52-Week Range

biote Corp. (BTMD) currently trades at $1.59. The stock gained $0.08 (5.3%) in the most recent trading session. The 52-week high for BTMD is $4.75, which means the stock is currently trading -66.5% from its annual peak. The 52-week low is $1.35, putting the stock 17.8% above its annual trough. Recent trading volume was 360K shares, suggesting relatively thin trading activity.

Is BTMD Overvalued or Undervalued? — Valuation Analysis

biote Corp. (BTMD) carries a value factor score of 80/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 1.15x, compared to the Healthcare sector average of 23.63x — a discount of 95%. The price-to-sales ratio is 0.24x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, BTMD trades at 3.69x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, biote Corp. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

biote Corp. Profitability — ROE, Margins, and Quality Score

biote Corp. (BTMD) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. Return on assets (ROA) comes in at 38.7% versus the sector average of -33.1%.

On a margin basis, biote Corp. reports gross margins of 72.0%, compared to 71.5% for the sector. The operating margin is 20.7% (sector: -66.1%). Net profit margin stands at 21.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -2.5% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

BTMD Debt, Balance Sheet, and Financial Health

Balance sheet data for BTMD is evaluated through our stability factor. The current ratio is 1.22x, suggesting adequate working capital coverage. Total debt on the balance sheet is $103M. Cash and equivalents stand at $28M.

BTMD has a beta of 1.11, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for biote Corp. is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

biote Corp. Revenue and Earnings History — Quarterly Trend

In TTM 2026, biote Corp. reported revenue of $197M and earnings per share (EPS) of $0.86. Net income for the quarter was $42M. Gross margin was 72.0%. Operating income came in at $41M.

In FY 2025, biote Corp. reported revenue of $192M and earnings per share (EPS) of $0.86. Net income for the quarter was $32M. Revenue grew -2.5% year-over-year compared to FY 2024. Operating income came in at $36M.

In Q3 2025, biote Corp. reported revenue of $48M and earnings per share (EPS) of $0.26. Net income for the quarter was $9M. Revenue grew -6.7% year-over-year compared to Q3 2024. Operating income came in at $8M.

In Q2 2025, biote Corp. reported revenue of $49M and earnings per share (EPS) of $0.10. Net income for the quarter was $4M. Revenue grew -0.6% year-over-year compared to Q2 2024. Operating income came in at $11M.

Over the past 8 quarters, biote Corp. has demonstrated a growth trajectory, with revenue expanding from $49M to $197M. Investors analyzing BTMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BTMD Dividend Yield and Income Analysis

biote Corp. (BTMD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BTMD Momentum and Technical Analysis Profile

biote Corp. (BTMD) has a momentum factor score of 15/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

BTMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, biote Corp. (BTMD) ranks #490 out of 838 stocks based on the Blank Capital composite score. This places BTMD in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BTMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BTMD vs S&P 500 (SPY) comparison to assess how biote Corp. stacks up against the broader market across all factor dimensions.

BTMD Next Earnings Date

No upcoming earnings date has been announced for biote Corp. (BTMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BTMD? — Investment Thesis Summary

The quantitative profile for biote Corp. suggests caution. The value score of 80/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 15/100, a headwind for near-term performance. High volatility (stability score 34/100) increases portfolio risk.

In summary, biote Corp. (BTMD) earns a Reduce rating with a composite score of 42.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BTMD stock.

Related Resources for BTMD Investors

Explore more research and tools: BTMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BTMD head-to-head with peers: BTMD vs AZN, BTMD vs SLGL, BTMD vs VMD.